Institutions: Optimistic on Pharmaceutical Catalytic Opportunities,Guotai CSI BIOMEDICINE ETF(512290) Rises 3.86% Intraday

NewTimeSpace News: As of 13:08 on April 1, 2026, the CSI Biomedical Index (930726) surged 3.95%. Its constituent stocks posted strong gains: Rongchang Bio rose 10.30%, Asymchem Life 10.00%, Junshi Biosciences 8.84%, followed by Dizhe Pharmaceutical, BeiGene and other stocks. Guotai CSI BIOMEDICINE ETF(512290) rose 3.86% to 1.00 CNY per share. Over the longer term, as of March 31, 2026, the ETF had risen 3.23% in the past week. (Stocks listed above are index constituents only and do not constitute specific investment recommendations.)

In terms of liquidity, Guotai CSI BIOMEDICINE ETFrecorded an intraday turnover rate of 2.86% with a trading volume of 109 million CNY. As of March 31, its average daily trading volume in the past week stood at 91.1984 million CNY.

In terms of scale, the latest scale of Guotai CSI BIOMEDICINE ETFreached 3.685 billion CNY. (Data source: Wind)

In terms of capital flows, the latest net capital outflow of the ETF was 23.2519 million CNY. Over the past 22 trading days, there were net capital inflows on 13 days, totaling 85.5585 million CNY, with an average daily net inflow of 3.8890 million CNY. (Data source: Wind)

Data showed that leveraged funds continued to allocate to the ETF. Its latest margin purchase amount reached 4.5378 million CNY, with a margin balance of 133 million CNY. (Data source: Wind)

As of March 31, the net asset value of Guotai CSI BIOMEDICINE ETFhad risen 1.48% in the past year. Since inception, the ETF’s highest monthly return was 23.26%, longest consecutive rising months 8 months, longest consecutive rise 109.28%, and average return in rising months 6.56%.

Since inception, the ETF had outperformed its benchmark by an annualized return of 2.52% as of March 31, 2026.

In terms of drawdown, the ETF’s relative benchmark drawdown year-to-date was 0.09% as of March 31.

On the fee front, the management fee is 0.50% and the custodian fee 0.10%.

In terms of tracking accuracy, the one-month tracking error was 0.005% as of March 31.

Guotai CSI BIOMEDICINE ETFclosely tracks the CSI Biomedical Index, which selects listed companies engaged in cell therapy, gene sequencing, blood products, biotech drugs, vaccines, in vitro diagnostics and other related products and services as index constituents to reflect the overall performance of biomedical listed companies.

As of March 31, 2026, the top 10 constituents of the CSI Biomedical Index (930726) were WuXi AppTec, Hengrui Medicine, Mindray Medical, Shanghai RAAS Blood Products, Changchun High-Tech, BeiGene, I-Mab, Gan & Lee Pharmaceuticals, Rongchang Bio and Asymchem Life, accounting for 67.83% of the index weight. (Stocks listed above are index constituents only and do not constitute specific investment recommendations.)

Great Wall Guorui Securities stated that the 2026 AACR Annual Meeting is upcoming, with increased participation by Chinese innovative drug companies. As a key global data release window for oncology innovative drugs, the AACR Annual Meeting is expected to serve as an important catalyst for the innovative drug sector in the next stage and further strengthen market recognition of the global competitiveness of China’s innovative drugs.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.